Effect of Pharmacogenomic Testing for Drug–Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA: The Journal of the American Medical Association
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial
JAMA 2022 Jul 12;328(2)151-161, DW Oslin, KG Lynch, MC Shih, EP Ingram, LO Wray, SR Chapman, HR Kranzler, J Gelernter, JM Pyne, A Stone, SL DuVall, LS Lehmann, ME Thase, , M Aslam, SL Batki, JM Bjork, FC Blow, LA Brenner, P Chen, S Desai, EW Dieperink, SC Fears, MA Fuller, CS Goodman, DP Graham, GL Haas, MB Hamner, AW Helstrom, RA Hurley, MS Icardi, GJ Jurjus, AM Kilbourne, J Kreyenbuhl, DJ Lache, SP Lieske, JA Lynch, LJ Meyer, C Montalvo, S Muralidhar, MJ Ostacher, GY Paschall, PN Pfeiffer, S Prieto, RM Przygodzki, M Ranganathan, MM Rodriguez-Suarez, H Roggenkamp, SA Schichman, JS Schneeweis, JA Simonetti, SR Steinhauer, T Suppes, MA Umbert, JL Vassy, D Voora, IR Wiechers, AE WoodFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.